Thursday, March 28, 2013
12:00 – 1:00 pm EST
To view the archived presentation, please click here.
On the Subject, Supreme Court Hears Oral Argument in "Pay-for-Delay" Patent Settlement Antitrust Case, published March 26, 2013
To reference the Supreme Court FTC v. Actavis, Inc. transcript held March 18, 2013, please click here.
McDermott Will & Emery is pleased to present another complimentary webcast in its regular "Life Sciences: Understanding Opportunities and Challenges for Improved Business Results" series. This webcast will focus on an analysis of the oral argument before the Supreme Court of the United States on Monday, March 25, 2013, in the case regarding the U.S. Court of Appeals for the Eleventh Circuit’s decision to uphold the settlement in the so-called Androgel case, which involved a so-called "reverse payment.” The outcome of this case will have profound implications for both branded and generic companies as they consider whether to litigate or settle — and how to settle — "bet the company" patent litigation.
Our distinguished panel will dissect the oral argument before the Supreme Court and forecast the Court's likely analysis of the critical issues.
M. Miller Baker, Partner
Jeffrey W. Brennan, Partner, Former Head of the FTC's Health Care Division
William G. Gaede, Partner
Glenn M. Engelmann, Senior Counsel, Former AstraZeneca U.S. General Counsel
For more information, please contact McDermott Events.
CLE credit for the live presentation of this program is pending in the following states: California, Illinois, New York, Texas and Virginia. A Uniform Certificate of Attendance will be made available to participants requesting CLE credit in all other states. Please be advised that CLE credit will not be approved for on demand/recorded viewings of this program in the states listed above. Attendees seeking credit in other states should consult their state CLE accrediting agency to determine whether self-study credit can be earned for on demand/recorded viewing of this program.